Changing the paradigm for treating motor fluctuations in Parkinson’s: advancements in COMT inhibition
Volume 6 January 2021, pages 28-37
Received: 21st October 2020; Accepted: 28th October 2020
Hubert H Fernandez
Center for Neurological Restoration, Cleveland Clinic Neurological Institute, Cleveland, Ohio, USA.
Columbia University Irving Medical Center, New York, New York, USA.
Joaquim J Ferreira
Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Support: This symposium was sponsored by Neurocrine Biosciences, Inc. and BIAL Pharmaceuticals.
We highlight the satellite symposium at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) 2020 reviewing the clinical manifestations and impact of the range of motor fluctuations in patients with Parkinson’s disease (PD). We focus on the pharmacology and role of catechol-O-methyltransferase (COMT) inhibition in the management of these motor fluctuations. Efficacy and safety data, including real-world experience for opicapone ▼ 50 mg as an adjunct to levodopa/dopa-decarboxylase inhibitor (DDCI) in the management of OFF episodes in patients with PD are then presented. Delegates’ questions are answered in a panel discussion.
Keywords:Parkinson's Disease, COMT Inhibitors, Opicapone, Motor Fluctuations, Wearing-Off
Keep up to date with our latest
articles and journals